All In Biotech

Drug Trial Radar · NCT00091312

Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors

Last checked: Nov 19, 2026Latest source record: Feb 9, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,976 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,976

Planned (sponsor's estimate)

Start

Jun 2004

Primary completion

Not stated

Sponsor

Lead sponsor
Federation Francophone de Cancerologie DigestiveAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 9, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as irinotecan, leucovorin, and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known whether combination chemotherapy is more effective than observation alone in treating patients who have undergone surgery for colon cancer. PURPOSE: This randomized phase III trial is studying irinotecan and fluorouracil with or without leucovorin to see how well they work compared to observation alone in treating patients who have undergone surgery for stage II colon cancer.

Conditions

  • Colorectal Cancer

Interventions

  • FOLFIRI regimenDrug

  • fluorouracilDrug

  • irinotecan hydrochlorideDrug

  • leucovorin calciumDrug

  • adjuvant therapyProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival at 5 years

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • National Cancer Institute - Cairo

    Cairo, Egypt

  • Centre Hospitalier Universitaire Ambroise Pare - Boulogne

    Boulogne-Billancourt, France

  • Hopital Du Bocage

    Dijon, France

  • Medizinische Klinik I

    Dresden, Germany

  • Ospedali Riuniti di Bergamo

    Bergamo, Italy

  • Azienda Ospedaliero Careggi

    Florence, Italy

  • Universita Degli Studi di Florence - Policlinico di Careggi

    Florence, Italy

  • Instituto Portugues de Oncologia Centro do Porto, S. A.

    Porto, Portugal

  • Hospital Universitario de Elche

    Elche Alicante, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.